As with short term treatment, prolonged treatment of orthotopic Brca1-wild type ovarian tumors with cisplatin, olaparib or their combination did not result in tumor regression or tumor growth arrest (Fig. S6 A, B). This evidence concerns the gene BRCA1 and ovarian neoplasm.